Klaus Romero

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6499849/publications.pdf

Version: 2024-02-01

49 papers	1,570 citations	394286 19 h-index	330025 37 g-index
51 all docs	51 docs citations	51 times ranked	2941 citing authors

#	Article	IF	Citations
1	Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease. JAMA Neurology, 2017, 74, 1178.	4.5	454
2	Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease inÂPatients With Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2017, 2, 442-450.	0.4	92
3	CredibleMeds.org: What does it offer?. Trends in Cardiovascular Medicine, 2018, 28, 94-99.	2.3	74
4	Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics. Europace, 2013, 15, 1042-1049.	0.7	69
5	Recommendations for the design of therapeutic trials for neonatal seizures. Pediatric Research, 2019, 85, 943-954.	1.1	52
6	The Coalition Against Major Diseases: Developing Tools for an Integrated Drug Development Process for Alzheimerâ€™s and Parkinsonâ€™s Diseases. Clinical Pharmacology and Therapeutics, 2009, 86, 365-367.	2.3	49
7	Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders. Orphanet Journal of Rare Diseases, 2019, 14, 36.	1.2	49
8	Understanding Placebo Responses in Alzheimer's Disease Clinical Trials from the Literature Meta-Data and CAMD Database. Journal of Alzheimer's Disease, 2013, 37, 173-183.	1.2	48
9	Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science. Digital Biomarkers, 2021, 4, 28-49.	2.2	43
10	Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death. Drug Safety, 2017, 40, 465-474.	1.4	38
11	Biomarkers for drug development in early psychosis: Current issues and promising directions. European Neuropsychopharmacology, 2016, 26, 923-937.	0.3	37
12	Assessing cardiovascular drug safety for clinical decision-making. Nature Reviews Cardiology, 2013, 10, 330-337.	6.1	36
13	Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis. Clinical and Translational Science, 2018, 11, 63-70.	1.5	36
14	Cerebrospinal Fluid Biomarkers for Alzheimerâ€™s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. Journal of Alzheimer's Disease, 2016, 55, 19-35.	1.2	35
15	The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2019, 9, 553-563.	1.5	29
16	Economic Burden and Disparities in Healthcare Resource Use Among Adult Patients with Cardiac Arrhythmia. Applied Health Economics and Health Policy, 2014, 12, 59-71.	1.0	28
17	Big data to smart data in Alzheimer's disease: Real-world examples of advanced modeling and simulation. , 2016, 12, 1022-1030.		28
18	Elements for Adequate Informed Consent in the Surgical Context. World Journal of Surgery, 2014, 38, 1594-1604.	0.8	26

#	Article	IF	Citations
19	Precompetitive Data Sharing as a Catalyst toÂAddress Unmet Needs in Parkinsonâ€™s Disease 1. Journal of Parkinson's Disease, 2015, 5, 581-594.	1.5	25
20	Pharmacometrics as a Discipline Is Entering the â€œIndustrializationâ€•Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success. Journal of Clinical Pharmacology, 2010, 50, 9S-19S.	1.0	20
21	Evaluation of Warfarin Drug Interaction Listings in US Product Information for Warfarin and Interacting Drugs. Clinical Therapeutics, 2011, 33, 36-45.	1.1	19
22	A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2017, 2, 451-460.	0.4	19
23	Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 441-455.	0.8	17
24	The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement. American Journal of Transplantation, 2019, 19, 625-632.	2.6	17
25	Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 545-552.	0.8	16
26	Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 457-467.	0.8	15
27	Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease. Clinical and Translational Science, 2019, 12, 240-246.	1.5	15
28	Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics. Journal of Antimicrobial Chemotherapy, 2020, 75, 392-399.	1.3	14
29	Open Data Revolution in Clinical Research: Opportunities and Challenges. Clinical and Translational Science, 2020, 13, 665-674.	1.5	14
30	Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data. Clinical Pharmacology and Therapeutics, 2020, 107, 796-805.	2.3	14
31	Effective Data Sharing as a Conduit for Advancing Medical Product Development. Therapeutic Innovation and Regulatory Science, 2021, 55, 591-600.	0.8	14
32	Striving for an integrated drug-development process for neurodegeneration: the coalition against major diseases. Neurodegenerative Disease Management, 2011, 1, 379-385.	1.2	13
33	Development of a Disease Progression Model for Leucineâ€Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs. Clinical Pharmacology and Therapeutics, 2020, 107, 553-562.	2.3	13
34	Clarification to the www.qtdrugs.org updated lists. Pharmacoepidemiology and Drug Safety, 2009, 18, 423-424.	0.9	12
35	Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin. AAPS Journal, 2018, 20, 47.	2.2	10
36	A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinsonâ€™s Disease in Participants With Leucineâ€Rich Repeat Kinase 2 Mutation. Clinical Pharmacology and Therapeutics, 2021, 110, 508-518.	2.3	8

#	Article	IF	Citations
37	Development of physiologicallyâ€based pharmacokinetic models for standard of care and newer tuberculosis drugs. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1382-1395.	1.3	8
38	Innovations in Therapy Development for Rare Diseases Through the Rare Disease Cures Accelerator-Data and Analytics Platform. Therapeutic Innovation and Regulatory Science, 2022, 56, 768-776.	0.8	8
39	Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases. Therapeutic Innovation and Regulatory Science, 2013, 47, 632-638.	0.8	7
40	Perspectives on statistical strategies for the regulatory biomarker qualification process. Biomarkers in Medicine, 2021, 15, 669-684.	0.6	7
41	Advancing tuberculosis drug regimen development through innovative quantitative translational pharmacology methods and approaches. International Journal of Infectious Diseases, 2017, 56, 208-211.	1.5	6
42	Open Data for Clinical Pharmacology. Clinical Pharmacology and Therapeutics, 2020, 107, 703-706.	2.3	5
43	Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol. Drug Safety, 2019, 42, 907-913.	1.4	3
44	Placebo effect in subjects with cognitive impairment. International Review of Neurobiology, 2020, 153, 213-230.	0.9	3
45	Time to Replace Bazett's QTâ€Correction. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1379-1380.	0.5	2
46	Association of patient demographics on quality of life in a sample of adult patients with cardiac arrhythmias. Quality of Life Research, 2014, 23, 129-134.	1.5	2
47	Hippocampal Neuroimagingâ€Informed Clinical Trial Enrichment Tool for Amnestic Mild Cognitive Impairment Using Open Data. Clinical Pharmacology and Therapeutics, 2020, 107, 903-914.	2.3	2
48	S3-02-01: Quantifying the placebo effect through modeling and simulation. , 2015, 11, P210-P210.		0
49	Graphical user interfaces for regulatoryâ€endorsed quantitative drug development tools in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e044029.	0.4	0